APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Human Coagulation Factor IX

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Recombinant Human Coagulation Factor IX Market Outlook and Growth Opportunities 2026

Report ID 174031480423 December 2025195 pages

Choose your research edition.

Industry ResearchRecombinant Human Coagulation Factor IX Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Human Coagulation Factor IX Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Recombinant Human Coagulation Factor IX Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Human Coagulation Factor IX Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Human Coagulation Factor IX Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Recombinant Human Coagulation Factor IX market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Recombinant Human Coagulation Factor IX is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Human Coagulation Factor IX is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Human Coagulation Factor IX is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Recombinant Human Coagulation Factor IX market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Recombinant Human Coagulation Factor IX market include Bio-Techne, Cayman, Cusabio, Grifols, IDELVION, NovoPro Bioscience, Octapharma, Sino Biological and Baxter, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Recombinant Human Coagulation Factor IX market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Human Coagulation Factor IX and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Human Coagulation Factor IX sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Recombinant Human Coagulation Factor IX market size, projected growth trends, production technologies, key applications, and end-use industries.

Recombinant Human Coagulation Factor IX Segment by Company

Bio-Techne

Cayman

Cusabio

Grifols

IDELVION

NovoPro Bioscience

Octapharma

Sino Biological

Baxter

Biogen

Diagbio

Hualan Bio

Sanofi

ChinaBiologic

Shuyang

Recombinant Human Coagulation Factor IX Segment by Type

500 IU/Bottle

250 IU/Bottle

2000 IU/Bottle

1000 IU/Bottle

Recombinant Human Coagulation Factor IX Segment by Application

Adult Patients

Child Patients

Recombinant Human Coagulation Factor IX Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Recombinant Human Coagulation Factor IX status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Recombinant Human Coagulation Factor IX market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Recombinant Human Coagulation Factor IX significant trends, drivers, influence factors in global and regions.

6. To analyze Recombinant Human Coagulation Factor IX competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Human Coagulation Factor IX market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Human Coagulation Factor IX and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Human Coagulation Factor IX.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Recombinant Human Coagulation Factor IX market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Recombinant Human Coagulation Factor IX industry.

Chapter 3: Detailed analysis of Recombinant Human Coagulation Factor IX manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Recombinant Human Coagulation Factor IX in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Recombinant Human Coagulation Factor IX in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Recombinant Human Coagulation Factor IX Industry Trends Table 2. Recombinant Human Coagulation Factor IX Industry Drivers Table 3. Recombinant Human Coagulation Factor IX Industry Opportunities and Challenges Table 4. Recombinant Human Coagulation Factor IX Industry Restraints Table 5. Global Recombinant Human Coagulation Factor IX Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Recombinant Human Coagulation Factor IX Revenue Share by Company (2021-2026) Table 7. Global Recombinant Human Coagulation Factor IX Sales Volume by Company (k units) & (2021-2026) Table 8. Global Recombinant Human Coagulation Factor IX Sales Volume Share by Company (2021-2026) Table 9. Global Recombinant Human Coagulation Factor IX Average Price (USD/unit) of Company (2021-2026) Table 10. Global Recombinant Human Coagulation Factor IX Company Ranking, (2024-2026) & (USD Million) Table 11. Global Recombinant Human Coagulation Factor IX Key Company Manufacturing Base & Headquarters Table 12. Global Recombinant Human Coagulation Factor IX Company, Product Type & Application Table 13. Global Recombinant Human Coagulation Factor IX Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Recombinant Human Coagulation Factor IX by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 500 IU/Bottle Table 18. Significant Companies of 250 IU/Bottle Table 19. Significant Companies of 2000 IU/Bottle Table 20. Significant Companies of 1000 IU/Bottle Table 21. Global Recombinant Human Coagulation Factor IX Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Recombinant Human Coagulation Factor IX Sales Volume by Type (2021-2026) & (k units) Table 23. Global Recombinant Human Coagulation Factor IX Sales Volume by Type (2027-2032) & (k units) Table 24. Global Recombinant Human Coagulation Factor IX Sales Volume Share by Type (2021-2026) Table 25. Global Recombinant Human Coagulation Factor IX Sales Volume Share by Type (2027-2032) Table 26. Global Recombinant Human Coagulation Factor IX Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Recombinant Human Coagulation Factor IX Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Recombinant Human Coagulation Factor IX Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Recombinant Human Coagulation Factor IX Sales Value Share by Type (2021-2026) Table 30. Global Recombinant Human Coagulation Factor IX Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Adult Patients Table 32. Significant Companies of Child Patients Table 33. Global Recombinant Human Coagulation Factor IX Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Recombinant Human Coagulation Factor IX Sales Volume by Application (2021-2026) & (k units) Table 35. Global Recombinant Human Coagulation Factor IX Sales Volume by Application (2027-2032) & (k units) Table 36. Global Recombinant Human Coagulation Factor IX Sales Volume Share by Application (2021-2026) Table 37. Global Recombinant Human Coagulation Factor IX Sales Volume Share by Application (2027-2032) Table 38. Global Recombinant Human Coagulation Factor IX Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Recombinant Human Coagulation Factor IX Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Recombinant Human Coagulation Factor IX Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Recombinant Human Coagulation Factor IX Sales Value Share by Application (2021-2026) Table 42. Global Recombinant Human Coagulation Factor IX Sales Value Share by Application (2027-2032) Table 43. Global Recombinant Human Coagulation Factor IX Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Recombinant Human Coagulation Factor IX Sales by Region (2021-2026) & (k units) Table 45. Global Recombinant Human Coagulation Factor IX Sales Market Share by Region (2021-2026) Table 46. Global Recombinant Human Coagulation Factor IX Sales by Region (2027-2032) & (k units) Table 47. Global Recombinant Human Coagulation Factor IX Sales Market Share by Region (2027-2032) Table 48. Global Recombinant Human Coagulation Factor IX Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Recombinant Human Coagulation Factor IX Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Recombinant Human Coagulation Factor IX Sales Value Share by Region (2021-2026) Table 51. Global Recombinant Human Coagulation Factor IX Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Recombinant Human Coagulation Factor IX Sales Value Share by Region (2027-2032) Table 53. Global Recombinant Human Coagulation Factor IX Market Average Price (USD/unit) by Region (2021-2026) Table 54. Global Recombinant Human Coagulation Factor IX Market Average Price (USD/unit) by Region (2027-2032) Table 55. Global Recombinant Human Coagulation Factor IX Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Recombinant Human Coagulation Factor IX Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Recombinant Human Coagulation Factor IX Sales by Country (2021-2026) & (k units) Table 58. Global Recombinant Human Coagulation Factor IX Sales Market Share by Country (2021-2026) Table 59. Global Recombinant Human Coagulation Factor IX Sales by Country (2027-2032) & (k units) Table 60. Global Recombinant Human Coagulation Factor IX Sales Market Share by Country (2027-2032) Table 61. Global Recombinant Human Coagulation Factor IX Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Recombinant Human Coagulation Factor IX Sales Value Market Share by Country (2021-2026) Table 63. Global Recombinant Human Coagulation Factor IX Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Recombinant Human Coagulation Factor IX Sales Value Market Share by Country (2027-2032) Table 65. Bio-Techne Company Information Table 66. Bio-Techne Business Overview Table 67. Bio-Techne Recombinant Human Coagulation Factor IX Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 68. Bio-Techne Recombinant Human Coagulation Factor IX Product Portfolio Table 69. Bio-Techne Recent Development Table 70. Cayman Company Information Table 71. Cayman Business Overview Table 72. Cayman Recombinant Human Coagulation Factor IX Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 73. Cayman Recombinant Human Coagulation Factor IX Product Portfolio Table 74. Cayman Recent Development Table 75. Cusabio Company Information Table 76. Cusabio Business Overview Table 77. Cusabio Recombinant Human Coagulation Factor IX Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 78. Cusabio Recombinant Human Coagulation Factor IX Product Portfolio Table 79. Cusabio Recent Development Table 80. Grifols Company Information Table 81. Grifols Business Overview Table 82. Grifols Recombinant Human Coagulation Factor IX Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 83. Grifols Recombinant Human Coagulation Factor IX Product Portfolio Table 84. Grifols Recent Development Table 85. IDELVION Company Information Table 86. IDELVION Business Overview Table 87. IDELVION Recombinant Human Coagulation Factor IX Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 88. IDELVION Recombinant Human Coagulation Factor IX Product Portfolio Table 89. IDELVION Recent Development Table 90. NovoPro Bioscience Company Information Table 91. NovoPro Bioscience Business Overview Table 92. NovoPro Bioscience Recombinant Human Coagulation Factor IX Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. NovoPro Bioscience Recombinant Human Coagulation Factor IX Product Portfolio Table 94. NovoPro Bioscience Recent Development Table 95. Octapharma Company Information Table 96. Octapharma Business Overview Table 97. Octapharma Recombinant Human Coagulation Factor IX Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Octapharma Recombinant Human Coagulation Factor IX Product Portfolio Table 99. Octapharma Recent Development Table 100. Sino Biological Company Information Table 101. Sino Biological Business Overview Table 102. Sino Biological Recombinant Human Coagulation Factor IX Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Sino Biological Recombinant Human Coagulation Factor IX Product Portfolio Table 104. Sino Biological Recent Development Table 105. Baxter Company Information Table 106. Baxter Business Overview Table 107. Baxter Recombinant Human Coagulation Factor IX Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Baxter Recombinant Human Coagulation Factor IX Product Portfolio Table 109. Baxter Recent Development Table 110. Biogen Company Information Table 111. Biogen Business Overview Table 112. Biogen Recombinant Human Coagulation Factor IX Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Biogen Recombinant Human Coagulation Factor IX Product Portfolio Table 114. Biogen Recent Development Table 115. Diagbio Company Information Table 116. Diagbio Business Overview Table 117. Diagbio Recombinant Human Coagulation Factor IX Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. Diagbio Recombinant Human Coagulation Factor IX Product Portfolio Table 119. Diagbio Recent Development Table 120. Hualan Bio Company Information Table 121. Hualan Bio Business Overview Table 122. Hualan Bio Recombinant Human Coagulation Factor IX Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. Hualan Bio Recombinant Human Coagulation Factor IX Product Portfolio Table 124. Hualan Bio Recent Development Table 125. Sanofi Company Information Table 126. Sanofi Business Overview Table 127. Sanofi Recombinant Human Coagulation Factor IX Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 128. Sanofi Recombinant Human Coagulation Factor IX Product Portfolio Table 129. Sanofi Recent Development Table 130. ChinaBiologic Company Information Table 131. ChinaBiologic Business Overview Table 132. ChinaBiologic Recombinant Human Coagulation Factor IX Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 133. ChinaBiologic Recombinant Human Coagulation Factor IX Product Portfolio Table 134. ChinaBiologic Recent Development Table 135. Shuyang Company Information Table 136. Shuyang Business Overview Table 137. Shuyang Recombinant Human Coagulation Factor IX Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 138. Shuyang Recombinant Human Coagulation Factor IX Product Portfolio Table 139. Shuyang Recent Development Table 140. Key Raw Materials Table 141. Raw Materials Key Suppliers Table 142. Recombinant Human Coagulation Factor IX Distributors List Table 143. Recombinant Human Coagulation Factor IX Customers List Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Recombinant Human Coagulation Factor IX Product Image Figure 2. Global Recombinant Human Coagulation Factor IX Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Human Coagulation Factor IX Sales Value (2021-2032) & (US$ Million) Figure 4. Global Recombinant Human Coagulation Factor IX Sales (2021-2032) & (k units) Figure 5. Global Recombinant Human Coagulation Factor IX Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global Recombinant Human Coagulation Factor IX Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 500 IU/Bottle Image Figure 10. 250 IU/Bottle Image Figure 11. 2000 IU/Bottle Image Figure 12. 1000 IU/Bottle Image Figure 13. Global Recombinant Human Coagulation Factor IX Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Recombinant Human Coagulation Factor IX Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Recombinant Human Coagulation Factor IX Sales Volume Share by Type (2021-2032) Figure 16. Global Recombinant Human Coagulation Factor IX Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Recombinant Human Coagulation Factor IX Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Recombinant Human Coagulation Factor IX Sales Value Share by Type (2021-2032) Figure 19. Adult Patients Image Figure 20. Child Patients Image Figure 21. Global Recombinant Human Coagulation Factor IX Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Recombinant Human Coagulation Factor IX Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Recombinant Human Coagulation Factor IX Sales Volume Share by Application (2021-2032) Figure 24. Global Recombinant Human Coagulation Factor IX Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Recombinant Human Coagulation Factor IX Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Recombinant Human Coagulation Factor IX Sales Value Share by Application (2021-2032) Figure 27. Global Recombinant Human Coagulation Factor IX Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Recombinant Human Coagulation Factor IX Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Recombinant Human Coagulation Factor IX Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Recombinant Human Coagulation Factor IX Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Recombinant Human Coagulation Factor IX Sales Value (2021-2032) & (US$ Million) Figure 32. North America Recombinant Human Coagulation Factor IX Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Recombinant Human Coagulation Factor IX Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Recombinant Human Coagulation Factor IX Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Recombinant Human Coagulation Factor IX Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Recombinant Human Coagulation Factor IX Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Recombinant Human Coagulation Factor IX Sales Value (2021-2032) & (US$ Million) Figure 38. South America Recombinant Human Coagulation Factor IX Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Recombinant Human Coagulation Factor IX Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Recombinant Human Coagulation Factor IX Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Recombinant Human Coagulation Factor IX Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Recombinant Human Coagulation Factor IX Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • 500 IU/Bottle
  • 250 IU/Bottle
  • 2000 IU/Bottle
  • 1000 IU/Bottle
Applications
  • Adult Patients
  • Child Patients
Companies covered
  • Bio-Techne
  • Cayman
  • Cusabio
  • Grifols
  • IDELVION
  • NovoPro Bioscience
  • Octapharma
  • Sino Biological
  • Baxter
  • Biogen
  • Diagbio
  • Hualan Bio
  • Sanofi
  • ChinaBiologic
  • Shuyang

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Recombinant Human Coagulation Factor IX Sales Value (2021-2032)
  4. 1.2.2 Global Recombinant Human Coagulation Factor IX Sales Volume (2021-2032)
  5. 1.2.3 Global Recombinant Human Coagulation Factor IX Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Recombinant Human Coagulation Factor IX Market Dynamics
  1. 2.1 Recombinant Human Coagulation Factor IX Industry Trends
  2. 2.2 Recombinant Human Coagulation Factor IX Industry Drivers
  3. 2.3 Recombinant Human Coagulation Factor IX Industry Opportunities and Challenges
  4. 2.4 Recombinant Human Coagulation Factor IX Industry Restraints
3 Recombinant Human Coagulation Factor IX Market by Company
  1. 3.1 Global Recombinant Human Coagulation Factor IX Company Revenue Ranking in 2025
  2. 3.2 Global Recombinant Human Coagulation Factor IX Revenue by Company (2021-2026)
  3. 3.3 Global Recombinant Human Coagulation Factor IX Sales Volume by Company (2021-2026)
  4. 3.4 Global Recombinant Human Coagulation Factor IX Average Price by Company (2021-2026)
  5. 3.5 Global Recombinant Human Coagulation Factor IX Company Ranking (2024-2026)
  6. 3.6 Global Recombinant Human Coagulation Factor IX Company Manufacturing Base and Headquarters
  7. 3.7 Global Recombinant Human Coagulation Factor IX Company Product Type and Application
  8. 3.8 Global Recombinant Human Coagulation Factor IX Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Recombinant Human Coagulation Factor IX Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Recombinant Human Coagulation Factor IX Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Recombinant Human Coagulation Factor IX Market by Type
  1. 4.1 Recombinant Human Coagulation Factor IX Type Introduction
  2. 4.1.1 500 IU/Bottle
  3. 4.1.2 250 IU/Bottle
  4. 4.1.3 2000 IU/Bottle
  5. 4.1.4 1000 IU/Bottle
  6. 4.2 Global Recombinant Human Coagulation Factor IX Sales Volume by Type
  7. 4.2.1 Global Recombinant Human Coagulation Factor IX Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Recombinant Human Coagulation Factor IX Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Recombinant Human Coagulation Factor IX Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Recombinant Human Coagulation Factor IX Sales Value by Type
  11. 4.3.1 Global Recombinant Human Coagulation Factor IX Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Recombinant Human Coagulation Factor IX Sales Value by Type (2021-2032)
  13. 4.3.3 Global Recombinant Human Coagulation Factor IX Sales Value Share by Type (2021-2032)
5 Recombinant Human Coagulation Factor IX Market by Application
  1. 5.1 Recombinant Human Coagulation Factor IX Application Introduction
  2. 5.1.1 Adult Patients
  3. 5.1.2 Child Patients
  4. 5.2 Global Recombinant Human Coagulation Factor IX Sales Volume by Application
  5. 5.2.1 Global Recombinant Human Coagulation Factor IX Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Recombinant Human Coagulation Factor IX Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Recombinant Human Coagulation Factor IX Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Recombinant Human Coagulation Factor IX Sales Value by Application
  9. 5.3.1 Global Recombinant Human Coagulation Factor IX Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Recombinant Human Coagulation Factor IX Sales Value by Application (2021-2032)
  11. 5.3.3 Global Recombinant Human Coagulation Factor IX Sales Value Share by Application (2021-2032)
6 Recombinant Human Coagulation Factor IX Regional Sales and Value Analysis
  1. 6.1 Global Recombinant Human Coagulation Factor IX Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Human Coagulation Factor IX Sales by Region (2021-2032)
  3. 6.2.1 Global Recombinant Human Coagulation Factor IX Sales by Region: 2021-2026
  4. 6.2.2 Global Recombinant Human Coagulation Factor IX Sales by Region (2027-2032)
  5. 6.3 Global Recombinant Human Coagulation Factor IX Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Recombinant Human Coagulation Factor IX Sales Value by Region (2021-2032)
  7. 6.4.1 Global Recombinant Human Coagulation Factor IX Sales Value by Region: 2021-2026
  8. 6.4.2 Global Recombinant Human Coagulation Factor IX Sales Value by Region (2027-2032)
  9. 6.5 Global Recombinant Human Coagulation Factor IX Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Recombinant Human Coagulation Factor IX Sales Value (2021-2032)
  12. 6.6.2 North America Recombinant Human Coagulation Factor IX Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Recombinant Human Coagulation Factor IX Sales Value (2021-2032)
  15. 6.7.2 Europe Recombinant Human Coagulation Factor IX Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Recombinant Human Coagulation Factor IX Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Recombinant Human Coagulation Factor IX Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Recombinant Human Coagulation Factor IX Sales Value (2021-2032)
  21. 6.9.2 South America Recombinant Human Coagulation Factor IX Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Recombinant Human Coagulation Factor IX Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Recombinant Human Coagulation Factor IX Sales Value Share by Country, 2025 VS 2032
7 Recombinant Human Coagulation Factor IX Country-level Sales and Value Analysis
  1. 7.1 Global Recombinant Human Coagulation Factor IX Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Recombinant Human Coagulation Factor IX Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Recombinant Human Coagulation Factor IX Sales by Country (2021-2032)
  4. 7.3.1 Global Recombinant Human Coagulation Factor IX Sales by Country (2021-2026)
  5. 7.3.2 Global Recombinant Human Coagulation Factor IX Sales by Country (2027-2032)
  6. 7.4 Global Recombinant Human Coagulation Factor IX Sales Value by Country (2021-2032)
  7. 7.4.1 Global Recombinant Human Coagulation Factor IX Sales Value by Country (2021-2026)
  8. 7.4.2 Global Recombinant Human Coagulation Factor IX Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Recombinant Human Coagulation Factor IX Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Recombinant Human Coagulation Factor IX Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Recombinant Human Coagulation Factor IX Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bio-Techne
  2. 8.1.1 Bio-Techne Company Information
  3. 8.1.2 Bio-Techne Business Overview
  4. 8.1.3 Bio-Techne Recombinant Human Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bio-Techne Recombinant Human Coagulation Factor IX Product Portfolio
  6. 8.1.5 Bio-Techne Recent Developments
  7. 8.2 Cayman
  8. 8.2.1 Cayman Company Information
  9. 8.2.2 Cayman Business Overview
  10. 8.2.3 Cayman Recombinant Human Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Cayman Recombinant Human Coagulation Factor IX Product Portfolio
  12. 8.2.5 Cayman Recent Developments
  13. 8.3 Cusabio
  14. 8.3.1 Cusabio Company Information
  15. 8.3.2 Cusabio Business Overview
  16. 8.3.3 Cusabio Recombinant Human Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Cusabio Recombinant Human Coagulation Factor IX Product Portfolio
  18. 8.3.5 Cusabio Recent Developments
  19. 8.4 Grifols
  20. 8.4.1 Grifols Company Information
  21. 8.4.2 Grifols Business Overview
  22. 8.4.3 Grifols Recombinant Human Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Grifols Recombinant Human Coagulation Factor IX Product Portfolio
  24. 8.4.5 Grifols Recent Developments
  25. 8.5 IDELVION
  26. 8.5.1 IDELVION Company Information
  27. 8.5.2 IDELVION Business Overview
  28. 8.5.3 IDELVION Recombinant Human Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 IDELVION Recombinant Human Coagulation Factor IX Product Portfolio
  30. 8.5.5 IDELVION Recent Developments
  31. 8.6 NovoPro Bioscience
  32. 8.6.1 NovoPro Bioscience Company Information
  33. 8.6.2 NovoPro Bioscience Business Overview
  34. 8.6.3 NovoPro Bioscience Recombinant Human Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 NovoPro Bioscience Recombinant Human Coagulation Factor IX Product Portfolio
  36. 8.6.5 NovoPro Bioscience Recent Developments
  37. 8.7 Octapharma
  38. 8.7.1 Octapharma Company Information
  39. 8.7.2 Octapharma Business Overview
  40. 8.7.3 Octapharma Recombinant Human Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Octapharma Recombinant Human Coagulation Factor IX Product Portfolio
  42. 8.7.5 Octapharma Recent Developments
  43. 8.8 Sino Biological
  44. 8.8.1 Sino Biological Company Information
  45. 8.8.2 Sino Biological Business Overview
  46. 8.8.3 Sino Biological Recombinant Human Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sino Biological Recombinant Human Coagulation Factor IX Product Portfolio
  48. 8.8.5 Sino Biological Recent Developments
  49. 8.9 Baxter
  50. 8.9.1 Baxter Company Information
  51. 8.9.2 Baxter Business Overview
  52. 8.9.3 Baxter Recombinant Human Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Baxter Recombinant Human Coagulation Factor IX Product Portfolio
  54. 8.9.5 Baxter Recent Developments
  55. 8.10 Biogen
  56. 8.10.1 Biogen Company Information
  57. 8.10.2 Biogen Business Overview
  58. 8.10.3 Biogen Recombinant Human Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Biogen Recombinant Human Coagulation Factor IX Product Portfolio
  60. 8.10.5 Biogen Recent Developments
  61. 8.11 Diagbio
  62. 8.11.1 Diagbio Company Information
  63. 8.11.2 Diagbio Business Overview
  64. 8.11.3 Diagbio Recombinant Human Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Diagbio Recombinant Human Coagulation Factor IX Product Portfolio
  66. 8.11.5 Diagbio Recent Developments
  67. 8.12 Hualan Bio
  68. 8.12.1 Hualan Bio Company Information
  69. 8.12.2 Hualan Bio Business Overview
  70. 8.12.3 Hualan Bio Recombinant Human Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Hualan Bio Recombinant Human Coagulation Factor IX Product Portfolio
  72. 8.12.5 Hualan Bio Recent Developments
  73. 8.13 Sanofi
  74. 8.13.1 Sanofi Company Information
  75. 8.13.2 Sanofi Business Overview
  76. 8.13.3 Sanofi Recombinant Human Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Sanofi Recombinant Human Coagulation Factor IX Product Portfolio
  78. 8.13.5 Sanofi Recent Developments
  79. 8.14 ChinaBiologic
  80. 8.14.1 ChinaBiologic Company Information
  81. 8.14.2 ChinaBiologic Business Overview
  82. 8.14.3 ChinaBiologic Recombinant Human Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 ChinaBiologic Recombinant Human Coagulation Factor IX Product Portfolio
  84. 8.14.5 ChinaBiologic Recent Developments
  85. 8.15 Shuyang
  86. 8.15.1 Shuyang Company Information
  87. 8.15.2 Shuyang Business Overview
  88. 8.15.3 Shuyang Recombinant Human Coagulation Factor IX Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Shuyang Recombinant Human Coagulation Factor IX Product Portfolio
  90. 8.15.5 Shuyang Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Recombinant Human Coagulation Factor IX Value Chain Analysis
  2. 9.1.1 Recombinant Human Coagulation Factor IX Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Recombinant Human Coagulation Factor IX Sales Mode & Process
  6. 9.2 Recombinant Human Coagulation Factor IX Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Recombinant Human Coagulation Factor IX Distributors
  9. 9.2.3 Recombinant Human Coagulation Factor IX Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst